Library / Peptides / Immune Support / Thymalin
Emerging evidence · Grade B

Thymalin

Thymalin (Thymic Bioregulator Peptide Complex)
Evidence
Emerging
Route
Intramuscular injection
Frequency
Once daily
Category
Immune Support
TL;DR
Thymalin is a thymus-derived peptide complex from Russia that aims to restore the immune system's 'training center' as it ages. It has been used in Russian medicine for decades and some studies suggest immune benefits in older adults, but the evidence comes mainly from Russian sources and lacks the gold-standard trials needed to confirm effectiveness. People with autoimmune conditions should approach with caution.
Part 01 · How it works

Mechanism.

Thymalin is a polypeptide complex extracted from bovine thymus gland tissue, developed by Vladimir Khavinson and colleagues in the Soviet Union/Russia. It is used as an immunomodulatory agent, purported to restore thymic function, normalize T-cell populations, and improve immune surveillance in aging or immunocompromised individuals. It has been used in Russian clinical practice for decades and has accumulated some longitudinal observational data.

The thymus is the training academy for immune cells. As we age, the thymus shrinks and fewer immune cells get proper training. Thymalin is like sending a rejuvenation team into a closed academy to reopen classrooms and resume training new immune recruits.

Mechanism · technical
Thymalin contains a mixture of low-molecular-weight polypeptides (primarily below 10 kDa) derived from thymus extract. These peptides are proposed to stimulate thymic epithelial cell function, promote T-lymphocyte differentiation, normalize CD4/CD8 ratios, and upregulate IL-2 production. Khavinson's group has also proposed epigenetic mechanisms whereby thymic peptides modulate gene expression of immune-related genes in lymphocytes.
Part 02 · Dosing & administration

How it's taken.

Values below describe how Thymalin has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
10 mg
Intramuscular injection · Once daily
Duration
5-10 day cycles, repeated every 3-6 months

Thymic peptide bioregulator complex. Approved in Russia. Contains thymic polypeptide extract. Used for immune restoration in aging and post-chemotherapy. Not FDA-approved.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
Generally reported as well-tolerated in Russian clinical literature. Possible allergic reactions given bovine protein origin. Risk of autoimmune flare in predisposed individuals. Theoretical risk of over-stimulation of immune pathways.
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18 (unless under immunology specialist care)
×
Known hypersensitivity to thymalin, thymic extract, or any component
×
Organ transplant recipients on immunosuppression (may trigger rejection)
×
Active autoimmune disease in flare
Interactions
Immunosuppressants (tacrolimus, cyclosporine, mycophenolate)
Thymalin stimulates T-cell immunity; directly opposes immunosuppressive therapy and may trigger graft rejection
Major
Immune checkpoint inhibitors (nivolumab, pembrolizumab)
Additive immune activation; may increase risk of immune-related adverse events
Moderate
Corticosteroids
High-dose corticosteroids suppress thymic function and may reduce thymalin efficacy
Moderate
Labs to monitor
CBC with Differential
Baseline and monthly
Monitor immune cell populations (T-cell focus)
T-Cell Subsets (CD4, CD8, CD4/CD8 ratio)
Baseline and at end of cycle
Primary target of thymic bioregulator
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
General metabolic safety
Immunoglobulin Levels
Baseline and at end of cycle
Assess humoral immune response
Part 04 · Evidence

How strong is the evidence?

Scores derived from rating, indexed studies, regulatory status, and catalogued safety data for this peptide. Curated per-peptide scoring replaces this when available.

70
Grade C
Grade C. Signal is real but maturing. Treat results as directional until larger or independent replications land.
Clinical efficacy
Emerging signal across multiple indexed studies; effect sizes still firming up.
68
Study quality
3 indexed studies in our dataset. Designs vary — see Research log for per-study grades.
79
Regulatory clarity
Approved in one or more jurisdictions outside the US.
72
Safety profile
Based on 5 documented contraindications, 3 interactions, 4 lab checkpoints.
84
Long-term data
Long-horizon data not yet available outside research settings.
48
Part 05 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
2003
0
Thymalin and longevity: 6-year prospective study in elderly patients
A Russian study of elderly patients (60–80 years) receiving annual Thymalin courses reported reduced mortality and improved immune parameters compared to controls over 6 years.
Russian-language publication, non-randomized design, no independent replication, potential significant publication bias. Results should be treated as hypothesis-generating.
PMID 12687761 ↗
02
2012
0
Peptide bioregulators and immune function: thymic peptides in clinical practice
A review of Russian clinical experience with thymic peptide preparations including Thymalin reported normalization of T-cell subpopulations and improved clinical outcomes in immunocompromised patients.
Narrative review by originating research group. No controlled clinical data from outside Russia included.
PMID 22530413 ↗
03
2018
0
Thymic peptides and immune senescence in aging: mechanistic and clinical perspectives
A review noted that thymic peptide preparations have plausible immunobiological rationale and some clinical data supporting use in immunosenescence, while calling for Western RCTs.
Largely review of Russian literature. Authors acknowledge quality limitations and call for independently funded trials.
PMID 29425777 ↗
Part 06 · Cost & access

Where you can get it.

Regulatory status
Approved as a pharmaceutical in Russia and some Eastern European countries. Not approved by FDA or EMA. Available in Western markets as an unregulated research peptide or dietary supplement. Use in the US is off-label/unapproved.
The Peptide Column takes no affiliate commission from any source.
Part 07 · Your appointment

Questions to bring.

01
Has Thymalin been studied in populations comparable to mine, and are those studies published in peer-reviewed journals accessible outside Russia?
02
Could Thymalin worsen autoimmune conditions by stimulating immune activity?
03
How does Thymalin compare to Thymosin Alpha-1 (Zadaxin) in terms of evidence and regulatory status?
04
What immune biomarkers should be measured before and during treatment?